Recent Updates
Recently added Catalysts

Anti-angiogenesis

Phase 1

Tumors | Small molecule | Oncology |Amgen Inc.|Last Updated: May 15, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment71
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00093873Study Evaluating AMG 706 in Subjects With Advanced Solid TumorsPHASE1 COMPLETED 71 — — Jul 1, 2003Dec 1, 2006May 15, 2013 - —
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Dose limiting toxicity
Cycle 1
Secondary Endpoints
Dose selection
Study completion
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AMG 706EXPERIMENTALAMG 706 QD
Interventions
NameTypeDescription
Anti-angiogenesisDRUGAnti-angiogenesis
AMG 706DRUGAnti-angiogenesis
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: Exclusion Criteria:

Unlock Eligibility Criteria
Competitive Landscape -Brain Tumors 139 trials
CompanyTickerTrialsLead PhaseDrugs
NovoCure Ltd.NVCR5PHASE3Temozolomide, Pembrolizumab, Poly-ICLC, Peptides, Concurrent Optune and RT followed by Optune System alone
Jazz Pharmaceuticals Public Limited CompanyJAZZ4PHASE3Dordaviprone, Everolimus, ONC201, JZP3507, ONC206
Day One Biopharmaceuticals, Inc.DAWN2PHASE3Tovorafenib, Chemotherapeutic Agent
Nuvation Bio, Inc. Class ANUVB1PHASE3safusidenib
Tango Therapeutics, Inc.TNGX3PHASE3Vorasidenib, Temozolomide, TNG456, abemaciclib
Telix Pharmaceuticals Limited Sponsored ADRTLX2PHASE3TLX-101-Tx + Lomustine, 131I-IPA
Eli Lilly and CompanyLLY3PHASE2Abemaciclib, Temozolomide, LY3410738, Gemcitabine, Cisplatin
Pfizer Inc.PFE3PHASE2Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide
Novartis AG Sponsored ADRNVS3PHASE2Dabrafenib, Trametinib, Lu-NeoB, Ga-NeoB, Lu-DOTA-TATE
NeOnc Technologies Holdings, Inc.NTHI4PHASE2NEO100, NEO212, Ipilimumab, Pembrolizumab, Nivolumab
Exelixis, Inc.EXEL2PHASE2Zanzalintinib, Cabozantinib
CNS Pharmaceuticals, Inc.CNSP1PHASE2Berubicin, Lomustine
Black Diamond Therapeutics, Inc.BDTX1PHASE2silevertinib in combination with temozolomide, temozolomide
Actuate Therapeutics, Inc.ACTU1PHASE29-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin.
Rigel Pharmaceuticals, Inc.RIGL1PHASE2Olutasidenib + TMZ
Apollomics Inc. Class AAPLM1PHASE2APL-101
ImmunityBio IncIBRX1PHASE2Bevacizumab, PD-L1 t-haNK, N-803
Cooper Companies, Inc.COO1PHASE2Pre-radiation temozolomide.
Incyte CorporationINCY1PHASE2Ruxolitinib, Temozolomide
AstraZeneca PLCAZN2PHASE1AZD1390, Olaparib, Durvalumab, Physicians Choice systemic chemotherapy
Unlock Competitive Intelligence